Pharmaceutical

AbCellera Biologics is planning to break ground in late 2021 on a manufacturing plant for therapeutic antibodies in Vancouver, British Columbia. Supported by $175.6 million in federal funding, the 130,000-sf project will cost approximately CAD$240 million to build. Offering advanced production suites, labs, offices, and warehouse space, the GMP facility will enhance the country's ability to create vaccines in response to future pandemic threats.

Winstanley Enterprises broke ground in June of 2021 on a $100 million bioscience research center in New Haven, Conn. Designed by Elkus Manfredi Architects, the 10-story, 525,000-sf facility will provide leasable laboratory and office environments for biomedical companies and academic institutions. Featuring a large public plaza, the collaborative structure will include a 48,000-sf business incubator operated by BioLabs, a conference center, and a STEM classroom for K-12 education programs.

Kilroy Realty Corporation broke ground in June of 2021 on the second phase of construction at Oyster Point in South San Francisco. Comprising three buildings offering 860,000 sf of space, the $940 million project will provide leading-edge lab and office environments for biomedical and pharmaceutical tenants. LEED Gold sustainable design certification will be sought for the structures, which will incorporate 40,000-sf open floor plates, 22' by 33' column spacing, 16' floor-to-floor heights, and a floor load capacity of 125 pounds per square foot.

Pfizer is constructing the $465 million Modular Aseptic Processing (MAP) facility on its existing campus in Portage, Mich. Integrating advanced manufacturing technologies, the 400,000-sf project will feature next-generation automation systems for the production of sterile injectable pharmaceuticals. The project, which will create approximately 450 new jobs, is part of a $1.1 billion investment in Kalamazoo County. Ground was broken on the facility in March of 2021 and completion is expected in 2023. Production operations will commence in 2025. 

Trammell Crow Company opened the 301,260-sf Fulton Labs facility in Chicago in May of 2021. Developed in partnership with Portal Innovations, the 14-story life sciences hub provides leasable wet and dry research environments with column-free spans for maximum lab module efficiency. Offering vivarium access and 22,000 sf of luxury amenity space, the project incorporates mobile lab casework, overhead service carriers, robust mechanical and electrical systems, and smart windows for the protection of sensitive materials and equipment.

Moderna is initiating a major expansion of the 300,000-sf Moderna Technology Center in Norwood, Mass. Providing additional production capacity for mRNA vaccines and therapeutics, the 350,000-sf project will include the acquisition of a 240,000-sf structure and the renovation of existing buildings. Enabling a 50 percent increase in the plant's commercial COVID-19 vaccine output by early 2022, the new facilities will also support the creation of thousands of preclinical research samples per month.

Vermeulens has released its market outlook report for the first quarter of 2021. Key points include:

Greatland Realty Partners began construction in April of 2021 on Revolution Labs in Lexington, Mass. Designed by SGA, the three-story, 180,000-sf life sciences building will provide leasable laboratory and office facilities for biomedical and pharmaceutical companies.

The International Society for Pharmaceutical Engineering has announced the 2021 Facility of the Year Awards category winners. The awards include:

Life sciences developer IQHQ began construction in April of 2021 on the $1 billion Fenway Center in Boston. Created in collaboration with Meredith Management, the biomedical research hub will be situated over the Massachusetts Turnpike on an air rights deck. The amenity-rich campus will include two towers offering 960,000 sf of leasable lab and office space, 10,000 sf of ground-floor retail, and an automated parking garage.

Sanofi will begin construction in fall of 2021 on a vaccine manufacturing facility in Singapore. Representing an investment of $477 million over five years, the structure will comprise a central hub housing several fully digitalized modules that allow production of three to four vaccines simultaneously. Designed for maximal flexibility, the next-generation factory will integrate multiple technology platforms based on different cell types, allowing the delivery of specific vaccines to be prioritized according to public health needs.

Promega Corporation opened the 283,000-sf Kornberg Center in April of 2021 in Fitchburg, Wis. Designed by Ramlow/Stein and SmithGroup, the three-story facility provides advanced laboratories for core product and technology development in cellular and molecular biology, biochemistry, genetic identity, clinical diagnostics, and scientific applications.

Foghorn Therapeutics completed construction in March of 2021 on its 60,000-sf headquarters in Kendall Square in Cambridge, Mass. Spanning three renovated floors in the 500 Technology Square building, the collaborative facility provides leading-edge environments to support crucial biomedical research including chemistry and biology labs, open offices, conference rooms, and huddle rooms. TRIA designed the fast-track project, which was built by Wise Construction with R.W.

Brandywine Realty Trust began construction in March of 2021 on the $287 million West Tower at Schuylkill Yards in Philadelphia. The 28-story, 570,000-sf structure will provide 200,000 sf of laboratory and office space for biomedical and life sciences companies, as well as 9,000 sf of retail space and 326 luxury apartments. On the ninth floor, a 29,000-sf lifestyle club will offer a sophisticated fitness center, a swimming pool, lounges, conference rooms, and co-working venues.

Vibalogics is creating a 110,000-sf facility for the production of oncolytic viruses, viral vector vaccines, and viral vector gene therapy products in Boxborough, Mass. Supporting late-phase clinical and commercial manufacturing operations, the highly flexible structure will include 2,000-liter bioreactors, multiple cGMP production suites, offices, warehouse space, and labs for research, development, and quality control. The $150 million project involves the renovation of an existing R&D building previously occupied by Cisco Systems.